Masanori Kobayashi

Masanori Kobayashi

Auto-generated profile, based on publicly available information

Masanori Kobayashi

Department of Gastroenterology and Hepatology JA Toride Medical Center Ibaraki Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Internal Medicine
Verified
Journal Article
Open access
PDF file
MKMasanori Kobayashi
Masanori Kobayashi
SRShomei Ryozawa
Shomei Ryozawa
RARyuichiro Araki
Ryuichiro Araki
KNKoji Nagata
Koji Nagata
YTYuki Tanisaka
Yuki Tanisaka
TKTsutomu Kobatake
Tsutomu Kobatake
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

7 November 2020 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MKMasanori Kobayashi
Masanori Kobayashi
TTTomoaki Tashima
Tomoaki Tashima
KNKoji Nagata
Koji Nagata
SSShinichi Sakuramoto
Shinichi Sakuramoto
AOAkihiko Osaki
Akihiko Osaki
SRShomei Ryozawa
Shomei Ryozawa

23 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMasanori Kobayashi
Masanori Kobayashi
SRShomei Ryozawa
Shomei Ryozawa
HIHirotoshi Iwano
Hirotoshi Iwano
RARyuichiro Araki
Ryuichiro Araki
YTYuki Tanisaka
Yuki Tanisaka
TKTsutomu Kobatake
Tsutomu Kobatake
Although endoscopic papillectomy is useful for treating papillary tumors, it is associated with a high rate of complications including pancreatitis; therefore, safer treatment options are needed. We examined the utility of wire-guided endoscopic papillectomy by comparing the pancreatic duct stenting and pancreatitis rates before and after wire-guided endoscopic papillectomy was introduced at our institution. We retrospectively examined the data from 16 consecutive patients who underwent conventional endoscopic papillectomy between November 1995 and July 2005 and the data from 33 patients in whom wire-guided endoscopic papillectomy was first attempted at our institution between August 2005 and April 2017. We compared the pancreatic duct stenting and pancreatitis rates between the two groups. Of the 33 patients in whom wire-guided endoscopic papillectomy was first attempted, the procedure was completed in 21. Pancreatic duct stenting was possible in 30 of the 33 patients in whom wire-guided endoscopic papillectomy was attempted (91%), and this rate was significantly higher than that before the introduction of wire-guided endoscopic papillectomy (68.8%). The incidence of pancreatitis before the introduction of wire-guided endoscopic papillectomy was 12.5%, but after August 2005, the incidence was reduced by half to 6.1%, which includes those patients in whom wire-guided endoscopic papillectomy could not be completed. Although wire-guided endoscopic papillectomy cannot be completed in some patients, we believe that this method shows some potential for reducing the total incidence of post-endoscopic papillectomy pancreatitis owing to more successful pancreatic duct stenting.

7 October 2024 in Endoscopy International Open
Verified
Journal Article
Open access
PDF file
HKHiromune Katsuda
Hiromune Katsuda
MKMasanori Kobayashi
Masanori Kobayashi
GIGo Ito
Go Ito
AKAmi Kawamoto
Ami Kawamoto
SKSusumu Krimura
Susumu Krimura
RORyuichi Okamoto
Ryuichi Okamoto
Background and study aims Although small hypervascular tumors are suspected to be pancreatic neuroendocrine tumors (p-NENs), their diagnosis and treatment are challenging. This study evaluated the usefulness of endoscopic ultrasound-guided tissue acquisition (EUS-TA) for diagnosis of small p-NENs. Methods All p-NEN lesions that underwent EUS-TA at our hospital between April 2018 and December 2023 were retrospectively analyzed. The diagnostic sensitivity of EUS-TA and the concordance rate of grading with EUS-TA and surgical specimens were examined. The lesions were grouped by size. Results The diagnostic sensitivity of EUS-TA was analyzed for 82 lesions, of which 44 were compared with postoperative specimens for grading. The definitive diagnosis was neuroendocrine tumor (NET) in 75 lesions, neuroendocrine carcinoma in five lesions, and mixed neuroendocrine non-neuroendocrine neoplasm in two lesions. Thirty tumors were ≤10 mm, 30 were 10 to 20 mm, and 22 were >20 mm, and the diagnostic sensitivities were 96.7%, 96.7%, and 90.9%, respectively. Concordance rates for grading were 94.4%, 82.4%, and 77.8% for tumors ≤10 mm, 10 to 20 mm, and ≥20 mm, respectively, with Cohen’s kappa coefficients of 0.64, 0.48, and 0.40, respectively. Conclusions EUS-TA showed adequate diagnostic sensitivity and grading agreement for p-NENs of all sizes, allowing for determination of appropriate treatment.

1 January 2014 in Internal Medicine
Verified
Journal Article
Open access
PDF file
MKMasanori Kobayashi
Masanori Kobayashi
ASAkahito Sako
Akahito Sako
TOToshiko Ogami
Toshiko Ogami
SNSo Nishimura
So Nishimura
NANaoki Asayama
Naoki Asayama
NUNaomi Uemura
Naomi Uemura
Objective Stool cultures are expensive and time consuming, and the positive rate of enteric pathogens in cases of nosocomial diarrhea is low. The 3-day rule, whereby clinicians order a Clostridium difficile (CD) toxin test rather than a stool culture for inpatients developing diarrhea >3 days after admission, has been well studied in Western countries. The present study sought to validate the 3-day rule in an acute care hospital setting in Japan. Methods Stool bacterial and CD toxin test results for adult patients hospitalized in an acute care hospital in 2008 were retrospectively analyzed. Specimens collected after an initial positive test were excluded. The positive rate and cost-effectiveness of the tests were compared among three patient groups. Patients The adult patients were divided into three groups for comparison: outpatients, patients hospitalized for ≤3 days and patients hospitalized for ≥4 days. Results Over the 12-month period, 1,597 stool cultures were obtained from 992 patients, and 880 CD toxin tests were performed in 529 patients. In the outpatient, inpatient ≤3 days and inpatient ≥4 days groups, the rate of positive stool cultures was 14.2%, 3.6% and 1.3% and that of positive CD toxin tests was 1.9%, 7.1% and 8.5%, respectively. The medical costs required to obtain one positive result were 9,181, 36,075 and 103,600 JPY and 43,200, 11,333 and 9,410 JPY, respectively. Conclusion The 3-day rule was validated for the first time in a setting other than a Western country. Our results revealed that the "3-day rule" is also useful and cost-effective in Japan.

17 October 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMasanori Kobayashi
Masanori Kobayashi
HKHiromune Katsuda
Hiromune Katsuda
AMAya Maekawa
Aya Maekawa
KAKeiichi Akahoshi
Keiichi Akahoshi
RWRyosuke Watanabe
Ryosuke Watanabe
RORyuichi Okamoto
Ryuichi Okamoto
Despite the presence of various guidelines, diagnosing malignant intraductal papillary mucinous neoplasm (IPMN) continues to pose challenges. Furthermore, although endoscopic ultrasonography (EUS) offers high-resolution images, it has not yet recognized as the primary tool for malignancy diagnosis. The study objective was to develop a simplified and user-friendly scoring system to improve the diagnostic accuracy of malignant IPMNs. Additionally, the utility of EUS and its effect on diagnostic accuracy were assessed. We retrospectively collected the clinical data on 160 cases of resected IPMN at Tokyo Medical and Dental University Hospital from January 2008 to December 2022. We examined clinical features, computed tomography (CT) and magnetic resonance imaging (MRI) findings, and EUS results if available. We then calculated the odds ratio of malignancy for these factors and developed an IPMN malignancy prediction (IMAP) scoring system. There were 89 (55.6%) cases of benign IPMNs and 71 (44.4%) of malignant IPMNs. Eight clinical and imaging findings, including age, diabetes mellitus status, jaundice, CA19-9 level, enhancing mural nodules ≥5mm, thickened wall, and main duct dilatation, were significantly associated with malignancy. The IMAP score was calculated by assigning 0 to 2 points to these factors based on the odds ratio. The area under the receiver operating characteristic curve for the IMAP score was 0.78 [95% confidence interval (CI): 0.71–0.85] based on CT/MRI alone and improved to 0.81 (95% CI: 0.74–0.87) when EUS was added. When the total exceeds 5 points, the positive predictive value becomes 100% (95% CI: 95.9–100). In conclusion, the IMAP scoring system has demonstrated promise as a clinically useful tool, offering both simplicity and sufficient accuracy. It holds potential as an important decision criterion for determining the treatment approach for IPMN. Additionally, EUS contributes to enhancing the diagnostic accuracy of the IMAP scoring system, thereby enabling more precise decision-making.